Source: http://www.legislation.nsw.gov.au/fullhtml/inforce/subordleg+509+2006+cd+0+Y
Timestamp: 2013-05-25 16:01:42
Document Index: 335773598

Matched Legal Cases: ['art 3', 'art 4', 'art 1', 'art 2', 'art 4', 'art(1', 'art 3', 'art 3', 'art 5', 'art 3']

Drug Misuse and Trafficking Regulation 2006
[2006-509]
Repealed version for 19 December 2008 to 31 August 2011 (accessed 26 May 2013 at 02:01).
Repeal:The Regulation was repealed by sec 10 (2) of the Subordinate Legislation Act 1989 No 146 with effect from 1.9.2011.
File last modified 1 September 2011.
4 Approval by Director-General of Department of Health of
5 Exemption for Scene of Crime Officers
5A Exemption for Police Integrity Commission
6 Exemption for authorised persons participating in approved
7 Exemption for giving out information about approved
8 General exemption for pharmacists and staff
Part 3 Precursors and drug manufacture or production
9 Precursors and drug manufacture or production
10 Sales and storage of Schedule 1 precursors
11 Sales of Schedule 2 precursors
11A Sales of Schedule 3 apparatus
Part 4 Custody and analysis of drug exhibits
13 Delivery of substance for analysis
14 Order for destruction
15 Carrying out of analysis
16 Procedure after analysis
17 Storage of sealed packages
18 Analyst’s certificate
19 Significant variations in analysts’
19A Prescribed service activity level for licensed injecting
21 Certificate evidence from interstate analysts: section
Schedule 1 Precursors—section 24A and clause
Schedule 2 Precursors—section 24A and clause
Schedule 3 Drug manufacture or production
apparatus—section 24A and clause 11A
Schedule 4 Precursors—section 24B
Part 1 Preliminary1 Name of RegulationThis Regulation is the Drug Misuse and Trafficking Regulation
2006.2 Commencement(1) This Regulation commences on 1 September 2006, except as provided
by subclause (2).Note. This Regulation replaces the Drug Misuse and Trafficking Regulation
2000, which is repealed on 1 September 2006 by section 10 (2)
1989.(2) Clauses 10 (1) (b) and (c), (2)–(5), (7) and (8) and 11 and
Schedule 2 commence on 1 March 2007.3 Definitions(1) In this Regulation:analyst has
the same meaning as in section 43 of the Act.approved needle
exchange program means a program approved by the Director-General of
the Department of Health, as referred to in clause 4.authorised
person means a person who is authorised by the Director-General of
the Department of Health to participate in an approved needle exchange
program, as referred to in clause 4.the Act means
1985.(2) In this Regulation, a reference to anything done by an analyst
includes a reference to anything done by a person under the supervision of an
analyst.(3) Notes included in this Regulation do not form part of this
Regulation.Part 2 General4 Approval by Director-General of Department of Health of
needle exchange programs(1) The Director-General of the Department of Health may authorise a
specified person or a specified class of persons to participate in a program
approved by the Director-General to facilitate:(a) the supply to intravenous drug users of sterile hypodermic
syringes and sterile hypodermic needles, and any associated equipment, to
prevent the spread of contagious disease and minimise health risks associated
with intravenous drug use, and
(b) the giving out of information concerning hygienic practices in the
use of hypodermic syringes and hypodermic needles to prevent the spread of
(2) An authorisation under this clause is to be granted, and may be
revoked, in the same manner as an authorisation under the
Act.5 Exemption for Scene of Crime OfficersA member of the NSW Police Force who has been designated by the
Commissioner of Police as a Scene of Crime Officer is exempt from the
provisions of sections 10, 23 (1) and (2) and 25 (1) and (2) of the Act in
relation to every prohibited plant or prohibited drug to the extent necessary
to enable the member to carry out his or her duties as such an
officer.5A Exemption for Police Integrity Commission
officers(1) An officer of the Police Integrity Commission who has been
authorised by the Commissioner for the Police Integrity Commission for the
purposes of this clause is exempt from the provisions of sections 10, 23 (1)
and (2) and 25 (1) and (2) of the Act in relation to every prohibited plant or
prohibited drug to the extent necessary to enable the officer to carry out his
or her duties as such an officer.(2) In this clause:Commissioner
for the Police Integrity Commission has the same meaning as in the
1996.officer of
the Police Integrity Commission has the same meaning as officer of the
Commission has in the Police
Integrity Commission Act 1996.6 Exemption for authorised persons participating in approved
program(1) An authorised person is exempt from the provisions of sections 11,
19 and 20 of the Act, to the extent necessary to authorise the person:(a) to have in his or her possession, and to distribute, hypodermic
syringes and hypodermic needles, and any associated equipment, for use in the
administration of a prohibited drug capable of being so administered,
(b) to give out information concerning hygienic practices in the use
of hypodermic syringes and hypodermic needles to prevent the spread of
(2) The exemption applies only for the purpose of enabling the
authorised person to participate in an approved needle exchange
program.7 Exemption for giving out information about approved
programAny person is exempt from the provisions of sections 19 and 20 of
the Act, to the extent necessary to authorise the person to give out
information about the location and hours of operation of an approved needle
exchange program.8 General exemption for pharmacists and staffA pharmacist acting in the ordinary course of his or her
profession, and any person acting under the supervision of the pharmacist, is
exempt from the provisions of sections 11, 19 and 20 of the Act, to the extent
necessary to authorise the pharmacist or person:(a) to have in his or her possession, and to distribute, hypodermic
apparatus9 Precursors and drug manufacture or production
apparatus(1) The substances listed in Schedules 1 and 2 are specified as
precursors for the purposes of section 24A of the
Act.(1A) The types of apparatus listed in Schedule 3 are specified as drug
manufacture apparatus for the purposes of section 24A of the
Act.(1B) The substances listed in Column 1 of Schedule 4 are specified as
precursors for the purposes of section 24B of the
Act.(1C) The quantities specified in Column 2 of Schedule 4 in relation to
the substances specified in Column 1 of the Schedule are prescribed for the
purposes of section 24B of the Act(2) The substances listed in Schedules 1 and 2 are prescribed as
precursors for the purposes of section 45 of the
Act.(3) The types of apparatus listed in Schedule 3 are prescribed for the
purposes of section 45 of the Act.Note. The term substance is defined in section 3
of the Act as including preparation and admixture and all salts, isomers,
esters or ethers of any substance and all salts of those isomers, esters and
ethers.10 Sales and storage of Schedule 1 precursors(1) A person (supplier) must not supply any
Schedule 1 precursor to a person (receiver) unless the
receiver:(a) has an account with the supplier and payment for the supply is
made through the account, and
(b) has provided the supplier with an end user declaration,
(c) has furnished the supplier with proof of the receiver’s
(2) A supplier must not supply any Schedule 1 precursor to a receiver
unless at least 24 hours have passed following the completion by the receiver
of the requirements set out in subclause (1) (b) and
(c).(3) A supplier of any Schedule 1 precursor must store the precursor in
a manner that prevents any access to it by any person other than:(a) the supplier, or
(b) a person authorised in writing by the supplier to have access to
(4) A supplier who authorises in writing another person to have access
to any Schedule 1 precursor in accordance with subclause (3) (b) must:(a) keep a copy of that authorisation for the period of its effect and
the period of at least 2 years following the authorisation ceasing to have
(b) make any such copy available for inspection on request by a police
officer during business hours.
(5) A supplier must not supply any Schedule 1 precursor to a person
unless the supplier has recorded:(a) the name and quantity of the Schedule 1 precursor supplied,
(b) the date of supply of the Schedule 1 precursor from the
supplier’s premises.
(6) Subclauses (1), (2), (4) and (5) do not apply to the supply of a
substance referred to in paragraph (b) of the definition of Schedule 1 precursor
in subclause (9) if:(a) the substance is supplied for therapeutic use within the meaning
of the relevant therapeutic goods laws, and
(b) the substance is packaged and labelled in accordance with the
relevant therapeutic goods laws, and
(c) the supplier is authorised, by the relevant therapeutic goods
laws, to supply the substance.
(7) A supplier must make each end user declaration provided to the
supplier in accordance with subclause (1) (b), and each record made under
subclause (5), available for inspection on request by a police officer during
business hours.(8) A supplier must keep each end user declaration provided to the
subclause (5), for a period of at least 5 years.(8A) The only proof of identity that may be used for the purposes of
subclause (1) (including the provision of an end user declaration) is:(a) an Australian driver licence held by the receiver that displays a
photograph of the receiver, or
(c) a Photo Card held by a receiver and issued under the Photo Card Act
(9) In this clause:end user
declaration means a document, completed by a proposed receiver of a
Schedule 1 precursor, that specifies the following:(a) the name and address of the receiver,
(b) details of the receiver’s proof of identity furnished to the
supplier concerned (for example, details of a driver licence or
(c) the name and quantity of the Schedule 1 precursor to be
(d) the proposed date of supply of the Schedule 1 precursor from the
supplier’s premises,
(e) the intended use for the Schedule 1
relevant therapeutic
goods laws means:(a) the Poisons and Therapeutic
Goods Act 1966, and
(c) the Commonwealth therapeutic goods laws within the meaning of that
Act as those laws apply as a law of this State.
precursor means any of the following substances:(a) a substance listed in Schedule 1 (other than a substance referred
to in paragraph (b), (c) or (d)),
(b) Ephedrine, Phenylpropanolamine or Pseudoephedrine or a salt of
Ephedrine, Phenylpropanolamine or Pseudoephedrine,
(c) Phenylacetic acid or a salt or ester of Phenylacetic
(d) Anethole.
Note. The term substance in this clause
does not include a preparation, admixture, salts, isomers, esters or ethers of
any substance or a salt of those isomers, esters and ethers (see subclause
(10)). Accordingly, the definition of Schedule 1
precursor does not include a preparation, admixture, salts, isomers,
esters or ethers of any substance or a salt of those isomers, esters and
ethers, except where specifically provided for.(10) In this clause, a reference to a substance does not include a
reference to a preparation, admixture, salt, isomer, ester or ether of a
substance listed in Schedule 1 or a salt of such an isomer, ester or ether,
unless otherwise specified.Maximum penalty:(a) in the case of a corporation—100 penalty units for a first
offence or 150 penalty units for a second or subsequent offence,
(b) in the case of an individual—30 penalty units for a first
offence or 50 penalty units for a second or subsequent
11 Sales of Schedule 2 precursors(1) A person (supplier) must not supply any
Schedule 2 precursor to a person (receiver) unless the receiver
has furnished the supplier with proof of the receiver’s identity
and:(a) payment for the supply is made through an account that the
receiver has with the supplier, or
(b) the receiver has provided the supplier with an end user
(2) A supplier must not supply any Schedule 2 precursor to a person
unless the supplier has recorded:(a) the name and quantity of the Schedule 2 precursor supplied,
(b) the date of supply of the Schedule 2 precursor from the
(3) A supplier must make each end user declaration provided to the
subclause (2), available for inspection on request by a police officer during
business hours.(4) A supplier must keep each end user declaration provided to the
subclause (2), for a period of at least 2 years.(4A) The only proof of identity that may be used for the purposes of
(5) In this clause:end user
Schedule 2 precursor, that specifies the following:(a) the name and address of the receiver,
(c) the name and quantity of the Schedule 2 precursor to be
(d) the intended use for the Schedule 2
precursor means any substance listed in Schedule
2.(6) In this clause, a reference to a substance does not include a
substance listed in Schedule 2 or a salt of such an isomer, ester or ether,
11A Sales of Schedule 3 apparatus(1) A person (supplier) must not supply any
Schedule 3 apparatus to a person (receiver) unless the receiver
(2) A supplier must not supply any Schedule 3 apparatus to a person
unless the supplier has recorded:(a) the name and quantity of the Schedule 3 apparatus supplied,
(b) the date of supply of the Schedule 3 apparatus from the
subclause (2), for a period of at least 2 years.(5) The only proof of identity that may be used for the purposes of
(6) In this clause:end user
declaration means a document, completed by a proposed receiver of
any Schedule 3 apparatus, that specifies the following:(a) the name and address of the receiver,
supplier concerned,
(c) the name and quantity of the Schedule 3 apparatus to be
(d) the intended use for the Schedule 3
apparatus means any apparatus listed in Schedule
3.Maximum penalty:(a) in the case of a corporation—100 penalty units for a first
Part 4 Custody and analysis of drug exhibits12 Application of Part(1) This Part applies to a substance that a member of the NSW Police
Force knows or suspects to be a prohibited drug and:(a) that is in the custody of a member of the NSW Police Force,
(b) the quantity of which is not less than the traffickable quantity
for the prohibited drug concerned.
(2) It is immaterial whether a prohibited drug to which this Part
applies is or has come into the custody of a member of the NSW Police Force
through seizure or other means.13 Delivery of substance for analysis(1) As soon as practicable (but in no case later than 14 days) after a
substance to which this Part applies comes into the custody of a member of the
NSW Police Force, the whole of the substance must be given to an analyst for
analysis.(2) Immediately after a member of the NSW Police Force opens a package
that has been sealed under this Part or becomes aware that a package sealed
under this Part has been opened or tampered with, the whole of the contents of
the package must be given to an analyst for
analysis.14 Order for destruction(1) Immediately after an order is made under Part 3A of the Act for
the destruction of a prohibited drug to which this Part applies, the person
having the custody of the prohibited drug must arrange for an analyst to
inspect the package or packages containing the prohibited drug to determine
whether or not any package has been opened or tampered with since it was last
sealed.(2) The person having the custody of the prohibited drug must give the
whole of the contents of a package that is found to have been opened or
tampered with to the analyst for analysis.15 Carrying out of analysis(1) An analyst to whom a substance is given for analysis under clause
13 or 14 must carry out an analysis of it to determine whether it is a
prohibited drug and, if it is, to determine:(a) the identity of the prohibited drug, and
(b) the quantity or mass of the prohibited drug,
(c) the purity of the prohibited drug.
(2) If the substance is cannabis leaf, the analyst, after identifying
the substance, need only determine the quantity or mass of the cannabis
leaf.16 Procedure after analysis(1) After removing a sample of a substance that is given to an analyst
for analysis under clause 13 or 14, the analyst must place the balance of the
substance not required for analysis into one or more packages, securely seal
each package and mark each package with an identifying
mark.(2) After complying with subclause (1), the analyst must deliver each
sealed package, or cause each sealed package to be delivered, to the
Commissioner of Police or to a person, or to a person of a class of persons,
specified by the Commissioner for the purpose.17 Storage of sealed packages(1) A person to whom a package is delivered under clause 16 (2) must
store the package in a secure place determined by the Commissioner of
Police.(2) Subclause (1) has effect subject to any order made under Part 3A
of the Act requiring destruction of the prohibited drug concerned and,
accordingly, does not have effect to the extent that is necessary to secure
compliance with the order.18 Analyst’s certificateAn analyst who, under this Part, analyses a substance that is a
prohibited drug must prepare a certificate under section 43 (1) of the Act of
the result of the analysis that includes the following:(a) the identity of the prohibited drug,
(c) except in the case of cannabis leaf, the purity of the prohibited
certificatesIf a difference occurs between the findings recorded in two or
more certificates of an analyst concerning the same drug exhibit and the
analyst providing the later or latest certificate is of the opinion that the
difference is significant, that analyst must immediately forward a copy of all
certificates relating to the drug exhibit to the Director of Public
Prosecutions.Part 5 Miscellaneous19A Prescribed service activity level for licensed injecting
centre(1) For the purposes of section 36K (2) of the Act, the prescribed
service activity level for the licensed injecting centre is an average of at
least 208 client visits per day in each month.(2) Subclause (1) applies only in relation to a month beginning after
the commencement of this clause.20 SavingsAny act, matter or thing that, immediately before the repeal of
the Drug Misuse and
Trafficking Regulation 2000, had effect under that Regulation
is taken to have effect under this Regulation.21 Certificate evidence from interstate analysts: section
43For the purposes of the definition of analyst in section 43 (6) of the Act,
the following persons are prescribed:(a) an analyst within the meaning of the Drugs of Dependence Act 1989 of the
(b) an analyst within the meaning of the Poisons and Drugs Act 1978 of the
(c) an analyst within the meaning of the Misuse of Drugs Act of the Northern
(d) an analyst within the meaning of the Drugs Misuse Act 1986 of
(e) an analyst within the meaning of the Controlled Substances Act 1984 of South
(f) an analyst within the meaning of the Poisons Act 1971 of
(g) an analyst within the meaning of section 120 of the Drugs, Poisons and Controlled Substances Act
1981 of Victoria,
(h) an analyst within the meaning of the Misuse of Drugs Act 1981 of Western
Australia (being an analyst registered under section 203 of the Health Act 1911 of Western
10(Clauses 9 and 10)Acetic anhydride4-Amino butanoic acid (also known as Piperidinic
acid)AnetholeBoron tribromideBromo safroleBromobenzene1,4-Butanediol (also known as Tetramethyelene glycol,
hydroxybutanol or 1,4BD)1-Chloro-1-phenyl-2-aminopropaneEphedrineEphedroneEthyl phenyl acetateGamma butyrolactone (also known as 4-hydroxybutanoic acid lactone
or gBL)Gamma hydroxybutanoic acid (including salts) (also known as Gamma
hydroxybutyric acid)Hydriodic acid4-Hydroxybutanal (also known as
4-Hydroxybutyraldehyde)4-Hydroxy-butanoic acid nitrile (also known as
4-Hydroxybutyronitrile)4-Hydroxy-pentanoic acid (also known as Gamma
valerolactone)2-Hydroxytetrahydrofuran (also known as
Tetrahydro-2-furanol)Hypophosphite saltsHypophosphorous acid3,4-Methylenedioxyphenylpropan-2-one (also known as
3,4-Methylenedioxy-phenyl-2-propanone)N-MethylephedrineMethyl phenylacetateN-MethylpseudoephedrineNorpseudoephedrinePhenylacetamidePhenylacetic acidPhenylacetonitrilePhenylacetyl chloridePhenylpropanolamine1-Phenyl-2-chloropropane1-Phenyl-2-nitropropene1-Phenyl-2-propanol1-Phenyl-1-propanone (also known as Phenylethylketone,
Propiophenone)1-Phenyl-2-propanone1-Phenyl-2-propanone oximePhosphorus (red or white)Phosphorous acid (also known as Phosphonic acid)Piperonal (also known as 3,4-Methylenedioxy-benzaldehyde or
Heliotopine)PseudoephedrinePyridine2-Pyrrolidone (also known as Gamma butyrolactam)Safrole (also known as
5-(2-Propenyl)-1,3-Benzodioxide)Sassafras oilSchedule 2 Precursors—section 24A and clause
11(Clauses 9 and 11)N-Acetylanthranilic acid (also known as 2-Acetamidobenzoic
acid)Allybenzene (also known as 3-Phenyl-1-propene or
2-Propenyl-benzene)Ammonium formateAnthranilic acid (also known as 2-Aminobenzoic
acid)BenzaldehydeBenzyl bromide (also known as a-Bromotoluene)Benzyl chloride (also known as a-Chlorotoluene)CalciumChromic acid (including salts)Chromium trioxide (also known as Chromium (VI)
oxide)Ergometrine (also known as Ergonovine)ErgotamineEthanamine (also known as Monoethylamine)N-EthylephedrineN-EthylpseudoephedrineFormamideHydrobromic acid (also known as Hydrogen bromide
solution)Iodine (including iodine salts)Isosafrole (also known as 5-(1
Propenyl)-1,3-benzodioxile)LithiumLysergic acidMagnesiumMercuric chloride (also known as Mercury (II) chloride or Mercury
bichloride)Methylamine (gas) (also known as Aminomethane or
Monomethylamine)Methylammonium saltsN-MethylformamideNitroethaneNitromethanePalladium (including salts)PhenylalaninePiperidinePotassiumPropionic anhydrydeRaney nickelSodiumSodium borohydrideThionyl chlorideThorium (including salts)Schedule 3 Drug manufacture or production
apparatus—section 24A and clause 11A(Clauses 9 and 11A)Hydrogen sulfide gas cylinderHydrogen chloride gas cylinderHydrogen gas cylinderAmmonia gas cylinderMethylamine gas cylinderRound bottom reaction flask (capacity 500ml or
greater)Condenser (joint size B19 or greater)Splash headDistillation headHeating mantle (capacity 500ml or greater)Pill or tablet press (whether manual or mechanical)Rotary evaporatorSchedule 4 Precursors—section 24B(Clause 9)
Column 1Column 2SubstanceQuantityAcetic anhydride1.0L4-Amino butanoic acid (also known as Piperidinic
acid)1.5kgAnethole0.1LBoron tribromide0.25LBromobenzene0.5LBromo safrole0.05L1-Chloro-1-phenyl-2-aminopropane0.25kgEthyl phenyl acetate0.5kgGamma hydroxybutanoic acid (including salts) (also
known as Gamma hydroxybutyric acid)1.5LHydriodic acid1.0L4-Hydroxybutanal (also known as
4-Hydroxybutyraldehyde)1.5L4-Hydroxy-butanoic acid nitrile (also known as
4-Hydroxybutyronitrile)1.5L4-Hydroxy-pentanoic acid (also known as Gamma
valerolactone)1.5L2-Hydroxytetrahydrofuran (also known as
Tetrahydro-2-furanol)1.5LHypophosphite salts0.25kgHypophosphorous acid0.25L3,4-Methylenedioxyphenylpropan-2-one (also known as
3,4-Methylenedioxy-phenyl-2-propanone)0.05kgN-Methylephedrine0.25kgMethyl phenylacetate0.5kgN-Methylpseudoephedrine0.25kgNorpseudoephedrine0.25kgPhenylacetamide0.5kgPhenylacetic acid0.5kgPhenylacetonitrile0.5LPhenylacetyl chloride0.5L1-Phenyl-1-propanone (also known as
Phenylethylketone, Propiophenone)0.25LPhosphorus (red or white)0.1kgPhosphorous acid (also known as Phosphonic
acid)0.25LPiperonal (also known as
3,4-Methylenedioxy-benzaldehyde or Heliotopine)0.1kgPyridine1.0L2-Pyrrolidone (also known as Gamma
butyrolactam)1.5LSafrole (also known as
5-(2-Propenyl)-1,3-Benzodioxide)0.1LSassafras oil0.1LHistorical notesThe following abbreviations are used in the Historical notes:
Am amended LW legislation website Sch Schedule Cl clause No number Schs Schedules Cll clauses p page Sec section Div Division pp pages Secs sections Divs Divisions Reg Regulation Subdiv Subdivision GG Government Gazette Regs Regulations Subdivs Subdivisions Ins inserted Rep repealed Subst substituted Table of amending instrumentsDrug Misuse
and Trafficking Regulation 2006 (509). GG No 111 of 1.9.2006,
p 7146. Date of commencement, except cll 10 (1) (b) and (c), (2)–(5),
(7) and (8) and 11 and Sch 2, 1.9.2006, cl 2 (1); date of commencement of cll
10 (1) (b) and (c), (2)–(5), (7) and (8) and 11 and Sch 2, 1.3.2007, cl
2 (2). This Regulation has been amended as follows:
2007(38)Drug Misuse and Trafficking
Amendment (Precursors) Regulation 2007. GG No 24 of 2.2.2007,
p 609.Date of commencement of Sch 1 [1] [2] [10] and [11], 2.2.2007, cl 2 (1);
date of commencement of Sch 1 [3]–[9], 1.3.2007, cl 2
No 17Drug Summit Legislative Response
2008(552)Drug Misuse and Trafficking
Amendment Regulation 2008. GG No 155 of 5.12.2008, p
11721.Date of commencement, 12.12.2008, cl 2.
(594)Drug Misuse and Trafficking
Amendment (Police Integrity Commission Exemption) Regulation
2008. GG No 158 of 19.12.2008, p 12321.Date of commencement, on gazettal.
Cl 5Am 2007 No 27, Sch 4.11.Cl 5AIns 2008 (594), cl 2.Part 3, headingSubst 2007 (38), Sch 1 [1].Cl 9Subst 2007 (38), Sch 1 [2]. Am 2008 (552), Sch 1
[1] [2].Cl 10Am 2007 (38), Sch 1 [3]–[5]; 2008 (552), Sch
1 [3] [4].Cl 11Am 2007 (38), Sch 1
[6]–[8].Cl 11AIns 2007 (38), Sch 1 [9].Cll 12, 13Am 2007 No 27, Sch 4.11.Cl 19AIns 2007 No 17, Sch 2.Cl 21Ins 2007 (38), Sch 1 [10].Sch 1, headingSubst 2008 (552), Sch 1 [5].Sch 1Am 2008 (552), Sch 1 [6].Sch 2, headingSubst 2008 (552), Sch 1 [7].Sch 3, headingIns 2007 (38), Sch 1 [11]. Subst 2008 (552), Sch 1
[8].Sch 3Ins 2007 (38), Sch 1 [11].Sch 4Ins 2008 (552), Sch 1 [9].